United States Patent 7,339,053 (Scope, Claim Coverage, and Landscape)
US 7,339,053 is directed to a narrow genus of nucleoside analogs defined by a single structural motif at the 4′-carbon (4′-C substitution) and by halogenation at the 2-position (2′-deoxy / 2′,3′-dideoxy variants and 2-halo variants). The ten independent claim items supplied define a small, enumerated set of specific compounds rather than broad functional claim language. That structure-driven claim scope makes the patent estate highly substitution- and design-around-sensitive.
What does US 7,339,053 claim cover?
Answer: The patent claims 4′-C-substituted 2-halo adenosine derivatives with defined combinations of (i) 4′-C substitution (ethynyl, cyano), (ii) 2′-deoxy vs 2′,3′-dideoxy substitution patterns, (iii) 2-halo identity (fluoro, chloro), and (iv) optional 5′-phosphonate status in at least one member.
Claim scope in plain structure terms
From the ten claim definitions, the claimed compound set is built from:
- Base scaffold: “2-haloadenosine” with additional 4′-C substituted at the 4′-position.
- 4′-C substituent options in the claims:
- 2-position halogen identity:
- Sugar substitution pattern:
- 2′-deoxy (claims 1, 2, 3, 4)
- 2′,3′-dideoxy (claims 5, 6, 7, 8, 9, 10)
- 5′-substitution variant:
- One member includes 5′-H-phosphonate (claim 4)
Enumerated claim members (coverage map)
The claims you provided appear to enumerate the following structures (grouped by substitution class):
A. 2′-deoxy, 4′-C-ethynyl, 2-fluoro
- Claim 1: 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine
- Claim 4: 2′-deoxy-4′-C-ethynyl-2-fluoroadenosine 5′-H-phosphonate
- Claim 3: 2-chloro-2′-deoxy-4′-C-ethynyladenosine (2-chloro analog, ethynyl, 2′-deoxy)
B. 2′-deoxy, 4′-C-cyano, 2-fluoro
- Claim 2: 4′-C-cyano-2′-deoxy-2-fluoroadenosine
C. 2′,3′-dideoxy, 4′-C-ethynyl, 2-halo
- Claim 5: 2′,3′-didehydro-2′,3′-dideoxy-4′-C-ethynyl-2-fluoroadenosine
- Claim 7: 2′,3′-dideoxy-4′-C-ethynyl-2′-chloro? (as written: “2′,3′-dideoxy-4′-C-ethynyl-2-chloroadenosine”)
- Claim 8: 2′,3′-dideoxy-4′-C-ethynyl-2-fluoroadenosine
- Claim 10: 2′,3′-dideoxy-4′-C-ethynyl-2-chloroadenosine
D. 2′,3′-dideoxy, 4′-C-cyano (and 2-halo)
- Claim 6: 2′,3′-didehydro-2′,3′-dideoxy-4′-C-cyano-2-fluoroadenosine
- Claim 9: 2′,3′-dideoxy-4′-C-cyano-2-fluoroadenosine
Net effect: the ten items define a small “design space slice” defined by the 4′-C ethynyl or cyano motifs plus 2-fluoro or 2-chloro and the 2′-deoxy vs 2′,3′-dideoxy status. Direct infringement risk tracks whether the product contains the same core motif and halogen identity, not whether it merely has “similar antiviral activity.”
How broad are the claims: broad genus or narrow enumeration?
Answer: The claims you listed function as a tight enumerated set of chemical compounds within a constrained structural class. The “4′-C-substituted-2-haloadenosine derivative” preamble supplies the class limitation, but each numbered claim appears to identify a specific chemical structure by substituent pattern.
Practical implication for infringement
For a competitor’s compound to land inside these claims, it must satisfy all required structural features simultaneously:
- 4′-C substituted: ethynyl or cyano as specified in the claimed members
- 2-halo identity: fluoro or chloro as specified
- sugar substitution: 2′-deoxy or 2′,3′-dideoxy (and in at least two places, “2′,3′-didehydro” language is used, which typically signals unsaturation differences that can matter for literal scope)
- 5′ group: only claim 4 includes the specific 5′-H-phosphonate feature
Design-around sensitivity points
If a generic or new entrant changes any of the following, the probability of falling outside literal coverage increases sharply:
- Swap 2-fluoro → 2-bromo or 2-iodo (not claimed)
- Swap 2-chloro → 2-fluoro (moves between claim members, but still stays in the “2-halo” set; depends on which product)
- Swap 4′-C-ethynyl → 4′-C-allyl, 4′-C-vinyl, 4′-C-alkynyl with different regiochemistry, or remove the C-substituted motif
- Change 2′-deoxy → 2′-OH (not claimed)
- Replace 5′-H-phosphonate with a different 5′ ester/prodrug configuration (likely outside claim 4)
What patents typically surround this kind of nucleoside analog claim?
Answer: For nucleoside reverse transcriptase / polymerase inhibitor analogs and adenosine analogs, nearby estates in the US commonly include:
- Compounds patents (structure claims like this one)
- Prodrug/formulation patents (phosphonate, phosphate ester, salt forms, delivery systems)
- Synthesis/process patents (intermediates and reaction sequences to install 4′-C substitution)
- Uses/method-of-treatment patents (indications and dosing regimens)
In this specific claim set, the only explicit functional “handle” is the 5′-H-phosphonate in claim 4. That often correlates with a broader prodrug landscape in the same family (phosphate/phosphonate variations), though those additional patents are not included in the information provided.
How does claim 4′-C substitution constrain the competitive landscape?
Answer: 4′-C substitution is the dominant structural differentiator. Competitors can often reduce patent exposure by changing the 4′-position chemistry while preserving the nucleoside pharmacophore at the 2-position and sugar ring.
4′-ethynyl vs 4′-cyano
- Ethynyl members (claims 1, 3, 4, 5, 7, 8, 10)
- Cyano members (claims 2, 6, 9)
If a development candidate keeps the same 2-fluoro / 2-chloro pattern but changes the 4′ substituent from ethynyl to cyano (or vice versa), it may move between claim subsets rather than eliminate coverage.
2-halo identity: fluoro vs chloro
The claim list includes both 2-fluoro and 2-chloro variants. A switch between fluoro and chloro does not inherently avoid coverage; it may still fall within one of the listed members.
Which claim members are most likely to matter in practice?
Answer: The most litigated or licensing-critical members are usually those that map to actual development molecules (drug substance, salt, and prodrug forms). Within your provided claims:
- Claim 1 and claim 8 represent 2′-deoxy and 2′,3′-dideoxy ethynyl-fluoro cores.
- Claim 3 and claim 10 represent 2′-deoxy and 2′,3′-dideoxy ethynyl-chloro cores.
- Claim 2 and claim 9 represent the cyano-fluoro cores.
- Claim 4 is narrower because it adds the 5′-H-phosphonate group, which often corresponds to a specific prodrug/depot configuration.
What does “2′,3′-didehydro-2′,3′-dideoxy” imply for scope?
Answer: That wording suggests an unsaturation element beyond simple dideoxy substitution. Even when two compounds are both “dideoxy,” unsaturation differences can create literal scope gaps. For infringement analysis, that phrase is a key discriminator between “2′,3′-dideoxy” and “2′,3′-didehydro-2′,3′-dideoxy” members.
In the claim set you provided:
- Claims 5 and 6 include “2′,3′-didehydro-2′,3′-dideoxy”
- Claims 8 and 9 (and likely 10 and 7) use the “2′,3′-dideoxy” phrasing without “didehydro”
That split matters for literal coverage if a product’s sugar ring geometry does not match the didehydro element.
Method-of-use, formulation, and prodrug exposure: what would be the likely next-layer IP?
Answer: Based on the inclusion of a phosphonate member (claim 4), this chemical scaffold class is plausibly covered in other patents for:
- Prodrug derivatives (phosphate/phosphonate salts, esters, and stereochemical variants)
- Synthesis intermediates (key 4′-C-ethynyl installation steps; protected sugar precursors)
- Analytical methods for identifying the compounds and intermediates (rarely asserted in litigation but common in some families)
Those layers are not specified in the data you supplied, so they cannot be mapped to numbered US patents here.
What litigation and exclusivity conclusions can be drawn from US 7,339,053 alone?
Answer: None. US 7,339,053 does not, by itself, establish:
- which marketed product (if any) corresponds to the claimed compounds,
- Orange Book status,
- FDA regulatory exclusivity periods,
- whether any Paragraph IV challenges were filed,
- or whether infringement suits settled.
Those conclusions require file history, family members, listed drug mapping, and litigation dockets, none of which are included in your input.
Key patent-estate takeaways specific to these claims
- Compound coverage is enumerated and motif-dependent. The claims demand the 4′-C substituted motif plus 2-halo identity plus a specific sugar substitution pattern.
- Ethynyl and cyano are separate claimed branches. Switching the 4′ substituent is the most direct design-around lever; switching among fluoro and chloro typically keeps the candidate in-range.
- The phosphonate member is a narrower foothold. If a competitor’s product uses a different 5′ group (different phosphonate form or an ester), claim 4 may not read.
- “Didehydro” vs “dideoxy” is a scope discriminator. Any unsaturation mismatch can move the candidate outside literal coverage.
Key Takeaways
- US 7,339,053 claims a narrow set of 4′-C-substituted, 2-halo adenosine derivatives with specific ethynyl or cyano 4′ substituents and defined 2′-deoxy vs 2′,3′-dideoxy (and didehydro) sugar patterns.
- The infringement question is primarily structural: matching the 4′-C motif, 2-halo identity, sugar substitution, and (for claim 4) the 5′-H-phosphonate.
- Design-around impact is highest for changes at the 4′ substituent and for any unsaturation differences tied to the “didehydro” language.
FAQs
1. Does US 7,339,053 cover all 4′-substituted adenosine derivatives?
No. It is limited to 4′-C substituted derivatives that also meet the “2-halo adenosine” and the enumerated 2′/2′,3′ substitution patterns reflected in the listed claim members.
2. If a compound has a 2′-deoxy and 2-fluoro adenosine core, is it automatically within the patent?
Not automatically. It must also match the claimed 4′-C substituent (ethynyl or cyano as specified) and the correct substitution state at 2′ (deoxy vs dideoxy/didehydro).
3. Is the 5′-H-phosphonate feature required for infringement of every claim?
Only claim 4 includes the explicit 5′-H-phosphonate feature. Other claims list non-phosphonate members in the set you provided.
4. How should “2′,3′-didehydro-2′,3′-dideoxy” be treated in claim construction?
As a structural limitation. Products lacking the didehydro element can fall outside the “didehydro” claim members while still potentially implicating the “dideoxy” members.
5. What is the fastest design-around lever against this patent?
Changing the 4′-C substituted motif away from the specific ethynyl/cyano definitions (or otherwise altering the 4′-position chemistry) offers the most direct pathway to avoid literal scope, with sugar and 2-halo identity changes providing additional separation.
References
- US Patent 7,339,053. United States Patent and Trademark Office.
